Centiva Capital’s Alaunos Therapeutics TCRT Stock Holding History

Centiva Capital’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-68	Closed	-$27K	–	1592
2021 Q2	$27K	Buy	+68	New	+$31.7K	﹤0.01%	1311

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Centiva Capital's TCRT Position: Q3 2021 in Review

Centiva Capital sold out of Alaunos Therapeutics (TCRT) in Q3 2021, closing a stake of 68 shares — an estimated $27K sold.

Centiva Capital first reported a position in TCRT in Q2 2021 and held it in 1 quarter. The position peaked at $27K in Q2 2021. 162 funds tracked by Wall St. Rank hold TCRT as of Q3 2021.

Centiva Capital reported no remaining Alaunos Therapeutics position as of Q3 2021 after selling out during the quarter.
Centiva Capital sold 68 Alaunos Therapeutics shares in Q3 2021, an estimated $27K.
Centiva Capital first reported a position in Alaunos Therapeutics in Q2 2021 and held it in 1 quarter.
Centiva Capital's Alaunos Therapeutics position peaked at $27K in Q2 2021.
162 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2021.

Based on Centiva Capital's 13F filing for Q3 2021, filed 15 Nov 2021.